Holen Sie sich die Stockscreener-App
5.07
0.20%
0.01
Handel nachbörslich:
5.07
Schlusskurs vom Vortag:
$5.06
Offen:
$5.13
24-Stunden-Volumen:
206.81K
Relative Volume:
0.40
Marktkapitalisierung:
$276.95M
Einnahmen:
$163.78M
Nettoeinkommen (Verlust:
$25.88M
KGV:
7.80
EPS:
0.65
Netto-Cashflow:
$-28.66M
1W Leistung:
-6.97%
1M Leistung:
-18.88%
6M Leistung:
-41.92%
1J Leistung:
-30.55%
1-Tages-Spanne:
$5.05
$5.145
1-Wochen-Bereich:
$4.99
$5.45
52-Wochen-Spanne:
$4.99
$10.66
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Firmenname
Voyager Therapeutics Inc
Sektor
Branche
Telefon
857-259-5340
Adresse
75 HAYDEN AVENUE, LEXINGTON, MA
Vergleichen Sie VYGR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
5.07 | 276.95M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Eingeleitet | Citigroup | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-10-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-26 | Eingeleitet | Guggenheim | Buy |
| 2024-03-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-07 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Eingeleitet | Truist | Buy |
| 2023-03-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-02-03 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-24 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-06 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-15 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-09-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-02-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-11-28 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-23 | Bestätigt | Stifel | Buy |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-28 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - Yahoo Finance
Barclays PLC Grows Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Insider Sell: Robin Swartz Sells Shares of Voyager Therapeutics Inc - GuruFocus.com
Voyager Therapeutics COO Robin Swartz sells $15,712 in stock By Investing.com - Investing.com South Africa
Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in Stock - MarketBeat
Voyager Therapeutics chief scientific officer sells shares worth $6,109 - Investing.com
Cantor Fitzgerald Predicts VYGR FY2024 Earnings - Defense World
Analysts Issue Forecasts for VYGR FY2024 Earnings - MarketBeat
Even though Voyager Therapeutics (NASDAQ:VYGR) has lost US$40m market cap in last 7 days, shareholders are still up 80% over 3 years - Simply Wall St
Voyager Therapeutics stock hits 52-week low at $5.18 By Investing.com - Investing.com Canada
Voyager Therapeutics stock hits 52-week low at $5.18 - Investing.com India
Cantor Fitzgerald Begins Coverage on Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Cantor Fitzgerald Initiates Coverage of Voyager Therapeutics (VYGR) with Overweight Recommendation - MSN
Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Trend Tracker for (VYGR) - Stock Traders Daily
Jane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Jane Street Group LLC Cuts Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - MarketBeat
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Purchased by Geode Capital Management LLC - Defense World
Barclays PLC Boosts Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by State Street Corp - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Position Reduced by State Street Corp - MarketBeat
Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
How to Take Advantage of moves in (VYGR) - Stock Traders Daily
Voyager Therapeutics COO Robin Swartz sells shares worth $36,725 By Investing.com - Investing.com Australia
Voyager Therapeutics COO Robin Swartz sells shares worth $36,725 - Investing.com India
Robin Swartz Sells 6,500 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock - MarketBeat
Insider Sell: Robin Swartz Sells 6,500 Shares of Voyager Therape - GuruFocus.com
Should Weakness in Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Simply Wall St
Charles Schwab Investment Management Inc. Buys 3,473 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Bought by Fmr LLC - Defense World
Long Term Trading Analysis for (VYGR) - Stock Traders Daily
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $17.00 Consensus PT from Brokerages - MarketBeat
BNP Paribas Financial Markets Has $288,000 Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Verition Fund Management LLC Purchases New Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
StockNews.com Downgrades Voyager Therapeutics (NASDAQ:VYGR) to Hold - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Downgraded by StockNews.com to Hold - MarketBeat
Voyager Therapeutics up 8% following quarterly beats - Seeking Alpha
Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Yahoo Finance
(VYGR) Trading Signals - Stock Traders Daily
Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High? - MSN
Erste Asset Management GmbH Purchases Shares of 1,058,378 Voyager Therapeutics, Inc. (NASDAQ:VYGR) - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Citigroup - Defense World
Voyager Therapeutics shares initiated with Buy rating by Citi, strong gene therapy pipeline - Investing.com Canada
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 Analysts - Benzinga
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Short Interest Update - Defense World
Wedbush assumes coverage of Voyager with outperform rating - MSN
Voyager Therapeutics (NASDAQ:VYGR) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Wedbush upgrades Voyager to Outperform on pipeline progress - Yahoo Finance
Finanzdaten der Voyager Therapeutics Inc-Aktie (VYGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):